This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
As my friends at #JPM this week are hearing in San Francisco, AI is part of virtually every biotech and med-tech story. Those of us who have worked in the health care ecosystem for some years know that the industry doesn’t change fast. As Shelly put it, we in industry have a responsibility.
Through its AI-based, non-invasive arrhythmia analysis technology, vMap, the company aims to improve cardiac ablation outcomes, optimize workflows, and increase procedural efficiency. TVM also invests in differentiated commercial-stage medicaltechnologies and late clinical-stage therapeutics.
By embracing technological advancements, focusing on personalised medicine, and addressing the challenges of chronic wounds, the industry can improve patient outcomes, reduce costs, and enhance the overall quality of care. The wound care market is poised for significant growth in 2025 and beyond.
This funding empowers Parker Health to further its position as the industry’s most compliant and competitive solution helping expand our medicaltechnology and services and to employ global teams. Parker Health has raised $26.3 million to date.
We aim to bring together relevant stakeholders, including payers, providers, patients groups, and biotech and when and where needed we cooperate with pharma, to be the one voice of the industry. Inna: Our aim is to improve patient and clinician access to modern, innovative and reliable medicaltechnology.
Dedicated Facilities: The new EIT Oxford campus includes over 30,000 square meters of research laboratory space, an oncology and wellness clinic, and facilities like AI GPU Supercluster Lab, Drug Design Lab, and Medical Device Lab, specifically dedicated to healthcare technology advancements.
Despite regulators’ moves to encourage digital innovation, the complex nature of the new types of devices, added to their speed of development, the ways data is used, and who by, means both the life sciences industry and the authorities will have to prepare for change.
The results of this Pew study tell us that consumers’ trust levels if various industry segments are low: especially for pharma, financial services, and marketers. What was intriguing about that research is that biotech was much more trusted than pharma, with biotech being seen as more innovative.
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content